Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback